The National Pediatric Rehabilitation Resource Center (C-PROGRESS) aims to facilitate research in pediatric rehabilitation science. The C-PROGRESS Pilot Studies program prioritizes innovative pilot studies and critical methodological advancements that will generate data to support larger-scale, competitive, and rigorous clinical trials.
The National Pediatric Rehabilitation Resource Center (C-PROGRESS) aims to facilitate research in pediatric rehabilitation science. The C-PROGRESS Pilot Studies program prioritizes innovative pilot studies and critical methodological advancements that will generate data to support larger-scale, competitive, and rigorous clinical trials.
The National Pediatric Rehabilitation Resource Center (C-PROGRESS) aims to facilitate research in pediatric rehabilitation science. The C-PROGRESS Pilot Studies program prioritizes innovative pilot studies and critical methodological advancements that will generate data to support larger-scale, competitive, and rigorous clinical trials.
Laura and Craig Hattersley traveled from the United Kingdom to Roanoke, Virginia, so their daughter Sarah, who was born with a rare CASK gene mutation, could receive four weeks of intensive therapy at the Fralin Biomedical Research Institute at VTC’s Neuromotor Research Clinic. “Sarah has come on leaps and bounds,” Laura Hattersley said as Sarah’s therapy wound down.
C-PROGRESS is currently accepting applications for funding in 2021. Letters of intent are due on Nov. 2, 2020. Principal investigators will be invited to submit proposals on Nov. 16, 2020, and applications are due on Dec. 18, 2020. Funding decisions will be announced in February, 2021.
The National Pediatric Rehabilitation Resource Center (C-PROGRESS) aims to facilitate research in pediatric rehabilitation science. The C-PROGRESS Pilot Studies program prioritizes innovative pilot studies and critical methodological advancements that will generate data to support larger-scale, competitive, and rigorous clinical trials.
The new National Pediatric Rehabilitation Resource Center, based at the institute and Virginia Tech, will expand and share the pioneering development of therapies at the clinic.
Called I-ACQUIRE, the Phase III clinic trial will examine the effectiveness of a pediatric therapy to increase upper extremity skills, gross motor development, and cognition in 240 children nationwide who experienced strokes when they were under 4 weeks old.
Evie was at her six-week-old checkup near Dublin, Ireland, when doctors noticed her head was not growing as fast as it should. Five months later, doctors diagnosed her with a rare genetic disorder – a form of microcephaly caused by a mutation in a gene called CASK.
